Tag Archives: FUTURE 5 study on psoriatic arthritis

Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study[1] PsA can lead to reduced mobility and irreversible joint damage[2]     FUTURE 5 is the largest randomized controlled … Read the full press release →